These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28705099)

  • 21. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leveraging DNA repair deficiency in gynecologic oncology.
    Walsh CS; Hodeib M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
    Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
    Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 32. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
    Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
    Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
    Incorvaia L; Passiglia F; Rizzo S; Galvano A; Listì A; Barraco N; Maragliano R; Calò V; Natoli C; Ciaccio M; Bazan V; Russo A
    Oncotarget; 2017 Apr; 8(14):23891-23904. PubMed ID: 28055979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitors: A new era of targeted therapy.
    Tangutoori S; Baldwin P; Sridhar S
    Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heating the patient: a promising approach?
    van der Zee J
    Ann Oncol; 2002 Aug; 13(8):1173-84. PubMed ID: 12181239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.